AK1320 MS / Asahi Kasei - LARVOL DELTA

First-In-Human Study of AK1320 Encapsulated Microspheres (AK1320 MS) (clinicaltrials.gov) - P1 | N=30 | Terminated | Sponsor: Asahi Kasei Pharma Corporation | Trial completion date: Dec 2024 ➔ Jan 2024 | Active, not recruiting ➔ Terminated | Trial primary completion date: Dec 2024 ➔ Nov 2023; Sponsor decision

Surgery • Trial completion date • Trial primary completion date • Trial termination • Musculoskeletal Diseases • Orthopedics

First-In-Human Study of AK1320 Encapsulated Microspheres (AK1320 MS) (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: Asahi Kasei Pharma Corporation | Recruiting ➔ Active, not recruiting | Trial completion date: Apr 2024 ➔ Dec 2024 | Trial primary completion date: Apr 2024 ➔ Dec 2024

Enrollment closed • Surgery • Trial completion date • Trial primary completion date • Musculoskeletal Diseases • Orthopedics

Emerging innovations for lumbar spondylolisthesis management: a systematic review of active and prospective clinical trials. (PubMed, Neurosurg Rev) - "Nearly half the trials (n = 18, 48.6%) include novel technologies; 6 (16.2%) are comparing surgical approaches, of which 4 (67%) include decompression alone versus decompression with instrumented fusion; 6 (16.2%) are evaluating perioperative pain management protocols, of which 3 (50%) include bupivacaine or ropivacaine; 3 (8.1%) are evaluating alternative medicines in LS; 2 (5.4%) are observational studies about the natural history of LS; 1 (2.7%) involves surgical infection prophylaxis; and 1 (2.7%) is evaluating AK1320 microspheres. LS can often require a multifaceted approach. Novel technologies and utilization of PROMs appear to be a significant emerging trend in LS management."

Journal • Review • Infectious Disease • Musculoskeletal Diseases • Pain

Asahi Kasei Pharma (BIO 2022) - "medical device). We also look for out-licensing opportunities of Recomodulin for CIPN and AK-1320 for spinal fusion."

Immunology • Musculoskeletal Diseases • Transplantation

First-In-Human Study of AK1320 Encapsulated Microspheres (AK1320 MS) (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: Asahi Kasei Pharma Corporation; Trial completion date: Apr 2023 ➔ Apr 2024; Trial primary completion date: Apr 2023 ➔ Apr 2024

Clinical • Trial completion date • Trial primary completion date • Musculoskeletal Diseases • Orthopedics

First-In-Human Study of AK1320 Encapsulated Microspheres (AK1320 MS) (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: Asahi Kasei Pharma Corporation; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Musculoskeletal Diseases • Orthopedics

First-In-Human Study of AK1320 Encapsulated Microspheres (AK1320 MS) (clinicaltrials.gov) - P1; N=40; Not yet recruiting; Sponsor: Asahi Kasei Pharma Corporation

Clinical • New P1 trial • Musculoskeletal Diseases • Orthopedics